KEY FIGURES
HORUS PHARMA
The performance of Horus Pharma is based on a reasoned dynamic of Research and Development, recruitment, and international conquest.
Recording two-digit growth since its inception, Horus Pharma ended the year 2022 with a turnover of €85 million. A good progress which is expected to continue with a forecast turnover over €100 million in 2023.
Horus Pharma is now a leading key player on its markets and continues its dynamic European expansion. Its headquarters are located in France in the Alpes-Maritimes. The company distributes its products in France, and internationally through its subsidiaries in Belgium, the Netherlands, Luxembourg, Spain, Switzerland, and Scandinavia, as well as in many other countries through distribution agreements.
BEYOND FIGURES, THE ACHIEVEMENTS
Horus Pharma growth is measured through tangible results in terms of hiring, product portfolio expansion and performance at the national and international levels.
EMPLOYMENT
With a sustained recruitment policy of 10% annual hiring, Horus Pharma has established itself as a thriving SME and employment generator in the Nice area.
INNOVATION
Innovation takes the form of a sustained rate of product launches, patent filing and expansion of the product portfolio, referencing more than 50 products covering all therapeutic segments in ophthalmology.
GENDER EQUITY
Since the creation of the laboratory, gender equality has always been favored and almost 70% of the company's staff are women, 40% of whom are on the Management Committee, including the President and founder.
International
Horus Pharma is now a leading key player on its markets and continues its dynamic European expansion. The company distributes its products in France, and internationally through its subsidiaries in Belgium, the Netherlands, Luxembourg, Spain, Switzerland, and Scandinavia, as well as in many other countries through distribution agreements.